Dapoxetine: a novel treatment for premature ejaculation

Area of Science:

• Pharmacology
• Urology
• Sexual Medicine

Background:

• Premature ejaculation (PE) significantly impacts individuals and partners, affecting sexual satisfaction and well-being.
• Current treatments, including daily selective serotonin reuptake inhibitors (SSRIs), have limitations such as slow onset and discontinuation issues.
• There is a need for effective on-demand therapies for PE.

Purpose of the Study:

• To evaluate the efficacy and safety of dapoxetine hydrochloride, a short-acting SSRI, for the on-demand treatment of premature ejaculation (PE).

Main Methods:

• Review of large phase III clinical studies investigating dapoxetine hydrochloride for PE.
• Assessment of pharmacokinetic profile, including rapid absorption and elimination.
• Evaluation of patient-reported outcomes related to ejaculatory control and sexual satisfaction.

Main Results:

• Dapoxetine hydrochloride demonstrated a significant increase in intravaginal ejaculatory latency time (IELT).
• Patient-reported outcomes showed improvements in perceived control over ejaculation and satisfaction with intercourse.
• The drug was generally well-tolerated, with a low incidence of adverse events and no reported SSRI discontinuation syndrome.

Conclusions:

• Dapoxetine hydrochloride is an effective and well-tolerated on-demand treatment option for premature ejaculation (PE).
• Its rapid pharmacokinetic profile makes it suitable for use as needed.
• Dapoxetine hydrochloride offers a valuable therapeutic advance for men with PE and their partners.